MS Drug Kesimpta Stops Disease in 91% of Patients
A new real-world study shows the MS therapy Kesimpta keeps disease stable in over 90% of patients, especially when started early. The findings support using high-effectiveness treatments sooner rather than waiting for the disease to progress.